Asset profile
Naptumomab estafenatox
Protein / enzyme therapeutic
Evidence outlook · no controlled comparison
NCT04880863 · Non-small Cell Lung Cancer
The lead study is single-arm or otherwise uncontrolled, so it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT04880863: The study was open-label, non-randomized, and had no control group, with 38 participants receiving naptumomab estafenatox in combination with docetaxel and obinutuzumab. Its imaging-based objective response endpoint was reported, but without a comparator there was no formal treatment comparison, so the findings provide limited evidence for naptumomab estafenatox.
Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
117 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 115 same-indication; 112 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Naptumomab Estafenatox: this drug | Phase 2/3 | Protein / enzyme therapeutic | 5T4 (trophoblast glycoprotein, TPBG) | ||
| TUB-030 | Phase 1/2 | Antibody–drug conjugate | 5T4 (trophoblast glycoprotein, TPBG) | ||
| XB010 | Phase 1 | Antibody–drug conjugate | 5T4 (trophoblast glycoprotein, TPBG) | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 |
…and 102 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
March 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.